Nifty
:
24013.10
Sensex
:
76802.90
-154.90 (-0.64%)
-607.08 (-0.78%)
Nifty
Sensex
:
:
24013.10
76802.90
-154.90 (-0.64%)
-607.08 (-0.78%)

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
68/99

BSE: 524404 | NSE: MARKSANS

NSE BSE
259.67
19-Jun-2026
  • Open
  • High
  • Low
  • Previous Close
  •  260.99
  •  265.36
  •  257.29
  •  261.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2398746
  •  625234316.98
  •  266.6
  •  155

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,791.32
  • 28.22
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 10,831.26
  • 0.35%
  • 3.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.87%
  • 1.90%
  • 28.33%
  • FII
  • DII
  • Others
  • 16.76%
  • 4.66%
  • 4.48%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.37
  • 13.77
  • 12.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.85
  • 9.25
  • 9.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.10
  • 10.03
  • 12.64

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.56
  • 21.02
  • 24.17

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.83
  • 3.21
  • 3.88

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.61
  • 11.82
  • 15.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
856.11
708.46
20.84%
754.43
681.85
10.64%
720.41
641.92
12.23%
619.99
590.62
4.97%
Expenses
660.69
581.52
13.61%
593.69
551.35
7.68%
575.92
495.11
16.32%
519.87
462.18
12.48%
EBITDA
195.42
126.93
53.96%
160.74
130.50
23.17%
144.49
146.81
-1.58%
100.12
128.44
-22.05%
EBIDTM
22.83%
17.92%
21.31%
19.14%
20.06%
22.87%
16.15%
21.75%
Other Income
35.17
15.34
129.27%
20.14
36.11
-44.23%
21.57
-0.07
-
5.64
14.95
-62.27%
Interest
6.31
3.44
83.43%
5.94
2.67
122.47%
5.81
2.63
120.91%
6.06
2.92
107.53%
Depreciation
24.29
22.74
6.82%
24.33
20.69
17.59%
26.92
19.51
37.98%
23.10
20.44
13.01%
PBT
200.00
116.09
72.28%
150.62
143.26
5.14%
133.33
124.60
7.01%
76.60
120.02
-36.18%
Tax
50.97
25.37
100.91%
36.93
38.19
-3.30%
34.20
26.84
27.42%
18.40
30.95
-40.55%
PAT
149.03
90.73
64.26%
113.69
105.07
8.20%
99.14
97.76
1.41%
58.20
89.07
-34.66%
PATM
17.41%
12.81%
15.07%
15.41%
13.76%
15.23%
9.39%
15.08%
EPS
3.27
2.00
63.50%
2.50
2.31
8.23%
2.17
2.13
1.88%
1.29
1.96
-34.18%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
2,950.94
2,622.84
2,177.41
1,852.14
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
Net Sales Growth
12.51%
20.46%
17.56%
24.23%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
 
Cost Of Goods Sold
1,277.28
1,143.74
1,038.12
921.36
716.81
595.05
567.83
498.01
523.13
458.74
509.69
Gross Profit
1,673.66
1,479.10
1,139.29
930.78
774.02
781.13
566.38
502.07
389.57
308.42
383.63
GP Margin
56.72%
56.39%
52.32%
50.25%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
Total Expenditure
2,350.17
2,094.21
1,718.83
1,512.82
1,231.96
1,036.58
941.96
867.93
834.31
734.24
760.91
Power & Fuel Cost
-
40.08
36.94
24.50
18.59
16.42
14.38
14.34
11.83
13.27
12.58
% Of Sales
-
1.53%
1.70%
1.32%
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
Employee Cost
-
350.30
293.64
239.37
220.30
197.32
168.42
159.07
147.75
149.70
122.42
% Of Sales
-
13.36%
13.49%
12.92%
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
Manufacturing Exp.
-
140.08
94.76
96.47
12.73
49.76
64.44
77.14
59.90
47.34
50.44
% Of Sales
-
5.34%
4.35%
5.21%
0.85%
3.62%
5.68%
7.71%
6.56%
6.17%
5.65%
General & Admin Exp.
-
117.60
93.90
52.79
37.74
50.67
45.52
51.03
42.51
37.52
36.01
% Of Sales
-
4.48%
4.31%
2.85%
2.53%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
Selling & Distn. Exp.
-
256.64
127.31
133.19
119.05
111.25
81.03
68.36
49.14
27.66
29.77
% Of Sales
-
9.78%
5.85%
7.19%
7.99%
8.08%
7.14%
6.84%
5.38%
3.61%
3.33%
Miscellaneous Exp.
-
45.77
34.16
45.14
106.73
16.10
0.34
0.00
0.05
0.00
29.77
% Of Sales
-
1.75%
1.57%
2.44%
7.16%
1.17%
0.03%
0%
0.01%
0%
0%
EBITDA
600.77
528.63
458.58
339.32
258.88
339.60
192.25
132.14
78.38
32.92
132.42
EBITDA Margin
20.36%
20.15%
21.06%
18.32%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
Other Income
82.52
70.38
50.42
59.31
41.85
6.69
0.33
4.63
8.47
18.86
12.72
Interest
24.12
11.66
11.20
9.13
8.45
7.99
8.75
9.66
10.22
6.79
10.16
Depreciation
98.64
83.39
74.27
51.85
44.78
36.15
26.66
22.80
26.84
30.09
28.13
PBT
560.55
503.97
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
Tax
140.50
121.35
108.63
72.33
60.70
63.63
36.42
23.87
14.00
3.56
24.11
Tax Rate
25.06%
24.08%
25.65%
21.42%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
PAT
420.06
380.58
313.69
266.31
184.56
235.94
117.02
76.46
32.94
8.83
78.51
PAT before Minority Interest
417.90
382.62
314.89
265.32
186.81
238.54
120.75
80.44
35.80
11.33
82.74
Minority Interest
-2.16
-2.04
-1.20
0.99
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
PAT Margin
14.23%
14.51%
14.41%
14.38%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
PAT Growth
9.78%
21.32%
17.79%
44.29%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
 
EPS
9.27
8.40
6.92
5.88
4.07
5.21
2.58
1.69
0.73
0.19
1.73

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,466.91
2,065.05
1,745.16
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
Share Capital
45.32
45.32
45.32
40.93
40.93
40.93
40.93
40.93
40.93
53.43
Total Reserves
2,421.60
2,019.74
1,699.85
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
Non-Current Liabilities
272.91
205.20
84.33
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
5.92
4.56
3.25
1.86
2.11
1.47
1.36
1.08
0.96
0.00
Current Liabilities
477.34
389.85
340.99
380.08
298.97
228.75
232.62
234.68
296.06
259.43
Trade Payables
305.70
268.28
230.60
200.08
168.66
110.33
106.07
77.83
161.78
118.98
Other Current Liabilities
117.17
70.62
42.20
96.80
79.69
58.86
20.90
10.08
0.71
0.68
Short Term Borrowings
23.09
29.09
41.59
41.29
18.74
18.84
99.91
117.41
109.71
87.89
Short Term Provisions
31.39
21.86
26.60
41.92
31.88
40.72
5.74
29.36
23.85
51.88
Total Liabilities
3,239.63
2,680.95
2,190.39
1,660.10
1,228.03
902.02
802.46
730.73
751.81
720.20
Net Block
981.96
775.94
486.31
428.31
309.36
302.72
269.73
279.38
266.98
269.65
Gross Block
1,413.02
1,134.80
828.26
726.26
551.92
565.39
506.26
495.35
456.49
429.47
Accumulated Depreciation
431.06
358.87
341.95
297.96
242.56
262.67
236.54
215.97
189.52
159.82
Non Current Assets
1,035.51
818.46
515.09
435.04
325.20
308.45
271.02
280.19
267.92
280.06
Capital Work in Progress
27.11
9.42
9.87
2.57
11.68
0.00
0.00
0.00
0.36
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
26.27
32.94
18.91
4.16
4.16
5.73
1.29
0.82
0.59
10.41
Other Non Current Assets
0.17
0.17
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
2,204.12
1,862.49
1,675.30
1,225.07
902.82
593.59
531.44
450.54
483.88
440.15
Current Investments
0.74
26.99
0.54
0.44
0.26
0.00
0.00
0.00
0.00
0.00
Inventories
845.52
617.94
484.74
424.44
404.32
241.84
293.25
218.12
190.09
167.79
Sundry Debtors
540.04
453.18
416.85
394.78
271.95
243.35
176.60
176.91
247.58
217.29
Cash & Bank
704.21
673.58
714.96
349.26
212.18
93.73
33.54
39.88
25.16
35.30
Other Current Assets
113.61
30.98
22.74
24.36
14.11
14.66
28.06
15.63
21.05
19.76
Short Term Loans & Adv.
81.20
59.82
35.48
31.79
0.98
3.40
0.00
0.00
20.96
19.76
Net Current Assets
1,726.78
1,472.64
1,334.31
844.98
603.85
364.83
298.82
215.86
187.82
180.71
Total Assets
3,239.63
2,680.95
2,190.39
1,660.11
1,228.02
902.04
802.46
730.73
751.80
720.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
206.66
230.41
237.41
99.26
178.59
233.33
27.40
50.09
14.06
30.80
PBT
503.97
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
Adjustment
69.37
55.42
74.24
35.31
56.57
42.04
31.88
43.99
26.58
39.63
Changes in Working Capital
-240.77
-126.19
-111.47
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
Cash after chg. in Working capital
332.56
352.76
300.43
172.12
227.12
258.33
54.40
57.56
35.44
58.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-125.90
-122.35
-63.01
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-49.01
-140.84
-259.21
-84.39
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
Net Fixed Assets
-141.06
-91.31
-21.45
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
Net Investments
26.25
-26.45
-29.78
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
Others
65.80
-23.08
-207.98
-60.12
-16.11
-35.71
9.59
-31.17
-6.39
62.82
Cash from Financing Activity
-65.15
-68.73
197.83
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
Net Cash Inflow / Outflow
92.51
20.84
176.03
94.38
118.46
60.19
-6.86
14.67
-10.14
-149.96
Opening Cash & Equivalents
403.28
382.44
206.41
112.03
93.73
33.54
39.72
25.05
35.30
185.27
Closing Cash & Equivalent
495.79
403.28
382.44
206.41
212.18
93.73
32.85
39.72
25.16
35.30

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
54.44
45.57
38.51
27.10
21.66
15.54
13.25
11.50
10.59
10.79
ROA
12.93%
12.93%
13.78%
12.94%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
ROE
16.89%
16.53%
18.59%
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
ROCE
22.50%
22.40%
22.89%
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
Fixed Asset Turnover
2.16
2.33
2.62
2.42
2.49
2.12
2.00
1.92
1.73
2.46
Receivable days
65.99
69.35
72.63
78.56
67.57
67.57
64.51
84.88
110.59
81.87
Inventory Days
97.24
87.89
81.36
97.65
84.73
86.10
93.32
81.63
85.14
60.86
Payable days
91.59
87.70
85.31
93.88
85.57
45.09
38.48
55.10
65.56
54.58
Cash Conversion Cycle
71.65
69.54
68.67
82.33
66.73
108.58
119.35
111.40
130.17
88.15
Total Debt/Equity
0.01
0.01
0.02
0.04
0.02
0.03
0.18
0.25
0.25
0.19
Interest Cover
44.22
38.80
37.99
30.31
38.84
18.97
11.80
5.87
3.20
11.52

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Marksans Pharma inks definitive pact to acquire 100% stake in QliniQ B.V.
    1st Jun 2026, 11:18 AM

    The company will acquire entire shareholding of QliniQ B.V. for a total consideration of 7.50 million euro

    Read More
  • Marksans Pharma - Quarterly Results
    27th May 2026, 00:00 AM

    Read More
  • Marksans Pharma gets USFDA’s final nod for Benzonatate Capsules
    1st Apr 2026, 14:42 PM

    This product is bioequivalent and therapeutically equivalent to the reference listed drug, Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.